All news from R&D

Experimental Treatment for Ebola Evaluated

A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. The Phase 1 clinical trial is examining the safety and tolerability of a single monoclonal antibody called mAb114, which was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and their collaborators. Investigators aim to enroll between 18 and 30 healthy volunteers aged 18 to 60. The trial will not expose participants to Ebola virus.

Target Genes For EBV Related Cancer Identified

VCU Massey Cancer Center has identified two genes that might be responsible for the replication of the Epstein-Barr virus, an infection that drives the growth of several types of cancer. The discovery could lead to the novel therapies for cancer.

Designer Immune Cells To Treat Leukemia

Chimeric antigen receptor T-cell therapy has produced some dramatic responses in pediatric acute lymphoblastic leukemia, but the responses have been less spectacular in other hematologic malignancies, and they have been disappointing in solid tumors.

A Rise In Elderly Prisoners In Japan

A prison, in Tokushima, 520 km west of Tokyo, a building to house elderly inmates, putting itself at the forefront of an effort to cope with Japan's gregarious prisoner population. The number of prisoners aged 60 or older has risen 7% from a decade ago to 9,308.